Cellromax Science Co., Ltd. Stock: price and insider trades · South Korea

Cellromax Science Co., Ltd., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to DART (FSS). The last twelve months, up to 2 November 2026, brought 8 filings signed by 7 insiders.

No insider sold shares on the market over the period. Instead, the filings list 8 purchases totalling €49k, made by 7 insiders. No amount is published for 5 filings, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. On the buying side, the filings list 2 senior executives, 1 board member and 1 chief executive among the declarants. One trade stands out by size: a purchase of €29k from 양인규, disclosed on 6 April 2026, or 0.10% of market capitalisation.

In all, 3 purchases were made within 30 days of a purchase by another insider of the company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The most recent open-market purchase was published on 7 April 2026, 217 days ago. The median gap between a trade and its publication by DART (FSS) is 6 days. This delay matters because a trade only becomes useful information once it is public.

For context, the typical company on the same exchange (median of 2,655 companies) published 7 filings over the same period, against 8 filings here. Our records for Cellromax Science Co., Ltd. go back to 2024, with 18 purchases and no sales on the open market in total.

Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.